The Influence of Multiple Oral Doses of Zileuton on the Steady-state Pharmacokinetics of Sulfasalazine and Its Metabolites, Sulfapyridine and N-acetylsulfapyridine

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1995 Jan 1

PMID 8620678

Citations 5

Authors

W M Awni

R A Braeckman

C S Locke

L M Dube

G R Granneman

Affiliations

Soon will be listed here.

Abstract

The effects of zileuton (Abbott-64077) on the pharmacokinetics of sulfasalazine (SASP) and its metabolites, sulfapyridine (SP) and N-acetylsulfapyridine (ASP), were studied in a randomised double-blind placebo-controlled study enrolling 14 healthy male volunteers. All subjects received SASP 1 g every 12 hours for 8 days and zileuton 800mg or placebo administered twice daily from day 4 to day 8 inclusive. Coadministration of zileuton did not significantly affect the area under the plasma concentration-time curve, the maximum (Cmax) or minimum (Cmin) plasma concentration and the time to Cmax of SASP, SP or ASP. Likewise, zileuton did not modify the terminal elimination half-life of SASP. It is concluded that coadministration of zileuton 1.6 g/day has no significant effects on the pharmacokinetics of SASP 2 g/day or its metabolites, SP and ASP.

Citing Articles

Benefit-risk assessment of antileukotrienes in the management of asthma.

Garcia-Marcos L, Schuster A, Perez-Yarza E Drug Saf. 2003; 26(7):483-518.

PMID: 12735786 DOI: 10.2165/00002018-200326070-00004.

Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.

Lowry P, Franklin C, Weaver A, Pike M, Mays D, Tremaine W Gut. 2001; 49(5):665-70.

PMID: 11600469 PMC: 1728511. DOI: 10.1136/gut.49.5.665.

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.

Lowry P, Franklin C, Weaver A, Szumlanski C, Mays D, Loftus E Gut. 2001; 49(5):656-64.

PMID: 11600468 PMC: 1728490. DOI: 10.1136/gut.49.5.656.

Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.

Dube L, Swanson L, Awni W Clin Rev Allergy Immunol. 1999; 17(1-2):213-21.

PMID: 10436867 DOI: 10.1007/BF02737605.

Clinically important drug interactions with disease-modifying antirheumatic drugs.

Haagsma C Drugs Aging. 1998; 13(4):281-9.

PMID: 9805209 DOI: 10.2165/00002512-199813040-00004.

References

Klotz U . Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet. 1985; 10(4):285-302. DOI: 10.2165/00003088-198510040-00001. View

Fischer C, Klotz U . High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man. J Chromatogr. 1979; 162(2):237-43. DOI: 10.1016/s0378-4347(00)81919-2. View

Eastwood M . Pharmacokinetic patterns of sulfasalazine. Ther Drug Monit. 1980; 2(2):149-52. DOI: 10.1097/00007691-198004000-00008. View

Das K, Eastwood M, MCMANUS J, Sircus W . The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut. 1973; 14(8):631-41. PMC: 1412758. DOI: 10.1136/gut.14.8.631. View

Fischer C, Klotz U . Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?. Ther Drug Monit. 1980; 2(2):153-8. DOI: 10.1097/00007691-198004000-00009. View

Israel E, Rubin P, Kemp J, Grossman J, Pierson W, SIEGEL S . The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993; 119(11):1059-66. DOI: 10.7326/0003-4819-119-11-199312010-00001. View

Carter G, Young P, Albert D, Bouska J, Dyer R, Bell R . 5-lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther. 1991; 256(3):929-37. View

Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E . Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol. 1992; 87(3):342-6. View

van Hees P, Tuinte J, van Rossum J, van Tongeren J . Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut. 1979; 20(4):300-4. PMC: 1412401. DOI: 10.1136/gut.20.4.300. View

10.

Schroder H, Evans D . Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects. Gut. 1972; 13(4):278-84. PMC: 1412167. DOI: 10.1136/gut.13.4.278. View

11.

Rouzer C, Samuelsson B . On the nature of the 5-lipoxygenase reaction in human leukocytes: enzyme purification and requirement for multiple stimulatory factors. Proc Natl Acad Sci U S A. 1985; 82(18):6040-4. PMC: 390695. DOI: 10.1073/pnas.82.18.6040. View

12.

Das K, Eastwood M . Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin Pharmacol Ther. 1975; 18(5 Pt 1):514-20. DOI: 10.1002/cpt1975185part1514. View

13.

Azadkhan A, TRUELOVE S, Aronson J . The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982; 13(4):523-8. PMC: 1402052. DOI: 10.1111/j.1365-2125.1982.tb01415.x. View

14.

Awni W, Braeckman R, Granneman G, Witt G, Dube L . Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600mg in healthy volunteers. Clin Pharmacokinet. 1995; 29 Suppl 2:22-33. DOI: 10.2165/00003088-199500292-00005. View